Novo and Lilly Intensify Competition in the GLP-1 Pill Market Ahead of Medicare Reform
Novo Nordisk and Eli Lilly are advancing competing oral GLP-1 receptor agonist programs as a landmark federal policy shift prepares to extend Medicare coverage for weight-management pharmacotherapy. Under the forthcoming benefit structure, eligible beneficiaries will access these agents at a fixed low monthly copayment a substantial departure from current out-of-pocket costs that have reached several hundred dollars per month.
Novo Nordisk reported that its oral GLP-1 agent surpassed three million prescriptions within five months of launch, with the company noting an acceleration in uptake following competitive market entry. Eli Lilly introduced its own oral weight-management agent earlier this spring and has indicated that prescription volumes are outpacing internal projections. The two manufacturers have adopted divergent positioning strategies.
Novo Nordisk has anchored its commercial messaging in cardiovascular outcome data, emphasising cardiometabolic risk reduction as a primary differentiator. Eli Lilly, by contrast, has highlighted the flexible dosing schedule of its agent which may be administered at any time relative to meals as a practical advantage for patients managing polypharmacy regimens.
Despite expanding formulary access, utilisation among eligible employees with obesity-related benefits remains below 20%. To address this gap, Eli Lilly has initiated a prospective study examining whether oral GLP-1 therapy reduces downstream healthcare utilisation, including hospitalisation rates and obesity-related comorbidity burden. Results are expected by the end of the year. Positive findings could support durable coverage decisions by commercial payers, many of which have restricted or suspended GLP-1 reimbursement in recent benefit cycles.
Eli Lilly disclosed phase trial results for an investigational obesity agent demonstrating mean body weight reduction of approximately 28% an outcome approaching the efficacy profile of bariatric surgery. The compound also produced improvements in sleep-disordered breathing and musculoskeletal pain. The company has indicated plans to pursue a direct-to-patient commercial model for this asset.
Novo Nordisk is advancing a dual-molecule combination in its obesity pipeline. Early-stage data have drawn comparisons with Lilly’s investigational compound, with some analysts noting a modest efficacy gap, though Novo Nordisk maintains that the combination demonstrates superiority over its existing approved agents. A regulatory submission decision from the US Food and Drug Administration is anticipated later this year.
The competitive dynamic between Novo Nordisk and Eli Lilly reflects a broader industry commitment to repositioning obesity as a chronic, treatable disease warranting sustained pharmacological intervention. A national pilot programme is underway to assess the long-term economic impact of GLP-1 therapy, with findings expected to inform future coverage determinations across both public and private payers. Sustained reimbursement support will likely require robust demonstration of population-level clinical and economic benefit.
